ArticleJTCVS open2026
Immunosenescence biomarkers and outcomes in isolated coronary artery bypass grafting.
Article in JTCVS open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Preoperative inflammation and immune dysregulation drive perioperative complications and long-term adverse outcomes in coronary artery bypass grafting (CABG). Routine blood count-derived immunosenescence biomarkers offer accessible measures of systemic immune status, but their prognostic value in CABG is not fully established. Methods: We conducted a retrospective cohort study of adults undergoing isolated CABG from 2010 to 2025. Preoperative immunosenescence biomarkers, including neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and aggregate index of systemic inflammation, were derived from routine blood counts collected within 30 days before surgery. Outcomes included 30-day mortality, perioperative complications, postoperative atrial fibrillation, all-cause mortality, and 5-point major adverse cardiovascular and cerebrovascular events. Associations were assessed using univariable and multivariable logistic and Cox regression adjusted for clinical covariates. Results: Among 9046 patients (median age 67 years; 24.3% female), 30-day perioperative mortality was 2.27%. Greater standardized preoperative biomarker levels were significantly associated with increased perioperative mortality ( Conclusions: Preoperative immunosenescence biomarkers are independently associated with adverse outcomes in patients who undergo CABG. These accessible biomarkers may identify high-risk patients scheduled to undergo CABG and guide future individualized perioperative and immunomodulatory strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.